Substance
ID:449271
Names and Identifiers
IUPAC name
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
Synonyms
RevlimidLenalidomideRevimid
IUPAC Traditional name
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
Registration numbers
CAS Number
Properties
Product Information
Application(s)
Used against multiple myeloma and myelodysplastic syndromes
Pharmacology Properties
Mechanism of Action
Interfering with the immune system and angiogenesis
Inhibits the expression of cyclooxygenase-2 (COX-2)
Molecule Details
No Data Available
Click here to submit data
Molecular Spectra
No Data Available
Click here to submit data
References
• Bennett et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer JAMA 2006;296(21):2558-2560
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 2005;42(4 Suppl 4):S3-8. PMID 16344099.
• Vellet, S et al Thalidomide and lenalidomide: mechanism-based potential drug combinations Leukemia and Lymphoma 2008;49(7):1238-1245
• List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57. PMID 15703420.
• Weber, DM et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl Med 2007;357(21):2133-2142
• Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Numer SD, Jagannath S, Dhodapkar MV.
• Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;epub ahead of print. PMID 16569772.
• Armoiry, X et al. Lenalidomide in the treatment of multiple myeloma: a review J of Clin Pharmacy & Therapeutics 2008;33:219-226